Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: Caregiver burden by treatment and clinical characteristics of patients with glioblastoma.
Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H, Cohen AL, Ormond DR, Chakravarti A, Willmarth N, Menon J, Ma J, Bauer H, Watanabe AH, Ulrich CM, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner D. Au TH, et al. Among authors: peters kb. Support Care Cancer. 2022 Feb;30(2):1377-1378. doi: 10.1007/s00520-021-06691-y. Support Care Cancer. 2022. PMID: 34792647 Free PMC article. No abstract available.
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, Kaley T, Colman H, McCluskey C, Gaffey S, Smith TR, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, Reardon DA. Nayak L, et al. Clin Cancer Res. 2021 Feb 15;27(4):1048-1057. doi: 10.1158/1078-0432.CCR-20-2500. Epub 2020 Nov 16. Clin Cancer Res. 2021. PMID: 33199490 Free PMC article. Clinical Trial.
Caregiver burden by treatment and clinical characteristics of patients with glioblastoma.
Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H, Cohen AL, Ormond DR, Chakravarti A, Willmarth N, Menon J, Ma J, Bauer H, Watanabe AH, Ulrich CM, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner D. Au TH, et al. Among authors: peters kb. Support Care Cancer. 2022 Feb;30(2):1365-1375. doi: 10.1007/s00520-021-06514-0. Epub 2021 Sep 11. Support Care Cancer. 2022. PMID: 34510238 Free PMC article.
Caregiver survey in glioblastoma focused on cognitive dysfunction: development and results from a multicenter study.
Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H, Cohen AL, Ormond DR, Neil EC, Chakravarti A, Willmarth N, Balajonda BC, Menon J, Ma J, Bauer H, Nelson RS, Tan MS, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner D. Au TH, et al. Among authors: peters kb. Future Oncol. 2023 Jan;19(2):173-188. doi: 10.2217/fon-2022-0904. Epub 2023 Mar 28. Future Oncol. 2023. PMID: 36974606
Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients.
Ranjan S, Leung D, Ghiaseddin AP, Taylor JW, Lobbous M, Dhawan A, Budhu JA, Coffee E, Melnick K, Chowdhary SA, Lu-Emerson C, Kurz SC, Burke JE, Lam K, Patel MP, Dunbar EM, Mohile NA, Peters KB. Ranjan S, et al. Among authors: peters kb. Cancer. 2024 May 1;130(9):1577-1589. doi: 10.1002/cncr.35220. Epub 2024 Jan 30. Cancer. 2024. PMID: 38288941 Review.
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Coan A, Threatt S, Friedman AH, Friedman HS. Reardon DA, et al. Among authors: peters kb. Cancer. 2011 Dec 1;117(23):5351-8. doi: 10.1002/cncr.26188. Epub 2011 May 16. Cancer. 2011. PMID: 21590689 Free PMC article. Clinical Trial.
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.
Reardon DA, Herndon JE 2nd, Peters KB, Desjardins A, Coan A, Lou E, Sumrall AL, Turner S, Lipp ES, Sathornsumetee S, Rich JN, Sampson JH, Friedman AH, Boulton ST, Bigner DD, Friedman HS, Vredenburgh JJ. Reardon DA, et al. Among authors: peters kb. Br J Cancer. 2012 Oct 23;107(9):1481-7. doi: 10.1038/bjc.2012.415. Epub 2012 Oct 4. Br J Cancer. 2012. PMID: 23037712 Free PMC article. Clinical Trial.
Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).
Affronti ML, Woodring S, Allen K, Kirkpatrick J, Peters KB, Herndon JE 2nd, McSherry F, Healy PN, Desjardins A, Vredenburgh JJ, Friedman HS. Affronti ML, et al. Among authors: peters kb. Support Care Cancer. 2016 Oct;24(10):4365-75. doi: 10.1007/s00520-016-3276-1. Epub 2016 Jun 6. Support Care Cancer. 2016. PMID: 27271867 Clinical Trial.
Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.
Chan A, Hertz DL, Morales M, Adams EJ, Gordon S, Tan CJ, Staff NP, Kamath J, Oh J, Shinde S, Pon D, Dixit N, D'Olimpio J, Dumitrescu C, Gobbo M, Kober K, Mayo S, Pang L, Subbiah I, Beutler AS, Peters KB, Loprinzi C, Lustberg MB. Chan A, et al. Among authors: peters kb. Support Care Cancer. 2019 Oct;27(10):3729-3737. doi: 10.1007/s00520-019-04987-8. Epub 2019 Jul 30. Support Care Cancer. 2019. PMID: 31363906 Free PMC article. Review.
123 results